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Abstract: Radiesse® (Bioform Inc, USA) is a sterile, latex-free, non-pyrogenic, semi-solid, 
cohesive subdermal, injectable implant, whose principal component is synthetic calcium hydrox-
ylapatite, a biocompatible material with over 20 years of use in medicine. The semi-solid nature 
of the product is created by suspending calcium hydroxylapatite microspheres of 25–45 microns 
diameter in a gel carrier of carboxymethylcellulose. The product has FDA approval for esthetic 
facial augmentation in the US. Such approval includes the long-lasting correction of moderate 
to severe facial wrinkles and folds and the treatment of facial fat loss due to immunodeﬁ  ciency 
virus infection. Diverse facial regions can be injected in order to ameliorate or enhance some 
features: glabellar lines, subdermal support of the brows, malar and buccal fat pads, tear 
troughs, nasolabial folds, nose, lips, perioral region, marionette lines, oral commisures and 
chin among others, as well as saucerized acne scars. Other medical indications include nipple 
projection for nipple areolar reconstruction, urinary incontinence, vesicoureteral reﬂ  ux, vocal 
cord augmentation, and use as a radiographic tissue marker. The average lasting result is from 
12 to 18 months. Radiesse can be considered an effective soft-tissue ﬁ  ller for overall longevity, 
biocompatibility, and low rate of side effects.
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Facial ﬁ  llers
Throughout recorded history, women and men have been trying to achieve and pre-
serve a youthful appearance, and many techniques have been designed in order to 
rejuvenate the face. The perception of beauty has been inﬂ  uenced all over the world 
and throughout history by many factors, including ethnic conditions, geographic loca-
tion, socioeconomic situation, and life styles, among others.
Over time, with exposure to sunlight, nutritional habits, and genetic patterns in 
addition to other factors, the skin starts lose its youthful appearance, especially in the 
face (Glogau 1996; Jacovella 2006). The most common esthetic signs of facial aging 
include visibility of bony landmarks, skin wrinkles, deep furrows, prominence of 
nasolabial folds, perioral vertical rhytids, ptosis of the oral commisures, and thinning 
of the lips. These changes arise from the loss of subcutaneous tissue, associated with 
thinning of the dermis (Glogau 1996; Jacovella 2006).
Facial rejuvenation treatments, both surgicaland non-surgical, try to meet patients’ 
needs according to their esthetic standards. A lot of procedures have been described to 
reverse some aging changes and attempt to achieve satisfactory facial rejuvenation.
To achieve success in esthetic medical procedures, it is necessary to have a well-
deﬁ  ned notion of beauty and be able to analyze and match the main patient features 
with his or her desires. Every year, more aging patients present themselves to the 
plastic surgeon or dermatologist requesting facial rejuvenation.
Conventional rejuvenation surgery likely remains the treatment of choice for 
patients requiring extensive esthetic facial changes (Jansen and Graivier 2003; Clinical Interventions in Aging 2008:3(1) 162
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Rohrich et al 2003). However, injectable facial ﬁ  llers are 
increasingly being seen as a very good option to ameliorate 
certain aging signs in patients who are not looking for a 
remarkable change in physical distinctiveness but to appear 
more rested and conﬁ  dent. These aging signs include glabellar 
lines, deep nasolabial folds, marionette lines, buccal com-
missures, peri-lips wrinkles, and other cases that need minor 
enhancement of some facial features (Jacovella 2007). In such 
cases, ﬁ  llers appear to provide more “real-time” results, not 
characterized by extensive swelling and prolonged recupera-
tive periods sometimes found in face lifts and other surgical 
procedures (Jacovella 2006; Jacovella et al 2006).
Furthermore, plastic surgeons often ﬁ  nd facial dermal ﬁ  ll-
ers to be a good complement to surgical rejuvenation proce-
dures such as a face lift, and to non-surgical procedures such 
as laser resurfacing treatments and chemical peels (Narins 
and Bowman 2005; Burroughs et al 2006; Roy et al 2006).
Materials were ﬁ  rst used for ﬁ  lling purposes more than 
100 years ago, when parafﬁ  n was injected into the scrotum, 
with terrible results (Klein and Elson 2000; Murray et al 
2005). In 1893, autologous fat transfer was described as a 
very good substitute material for soft tissue agumentation. 
Other materials including medical silicone were developed 
for the same purpose, but due do many severe complications, 
this substance has not remained one of choice (Murray et al 
2005). Complications associated with injectable liquid sili-
cone may occur at any time in the distant future, even after an 
initially successful treatment. The element of most concern 
is that when complications do occur, they frequently produce 
very difﬁ  cult or untreatable clinical situations (Rohrich and 
Potter 2004).
In the early 1970s, Stanford University investigators pre-
sented a preliminary study on injectable collagen. A decade 
or so later, collagen was approved by the FDA for medical 
use (Tzikas 2004; Kanchwala et al 2005). In some ways, the 
approval of collagen marked a milestone for esthetic practice. 
Its approval also served as a catalyst for the continuing search 
for better ﬁ  ller materials for the face. Since then, researchers 
have been driving both plastic surgeons and dermatologists 
by providing a wide range of options for facial ﬁ  llers.
Classiﬁ  cation and ideal properties 
of facial ﬁ  llers
Different classiﬁ  cations can be considered. Chemically, the 
available products can be classiﬁ  ed into two different catego-
ries: biologic and synthetic substances (Jacovella 2007).
Biologic materials include bovine collagen, animal 
hyaluronic acid, and autologous fat. Synthetic ﬁ  llers include 
non-animal hyaluronic acid, polymethyl methacrylate 
(PMMA) microspheres, and hydroxylapatite micro-particles, 
among others. Several authors have also described similar 
categories (Jansen and Graivier 2003, 2006; Rohrich et al 
2003; Tzikas 2004; Murray et al 2005; Narins and Bowman 
2005; Broder and Cohen 2006; Klein and Elson 2006; 
Sengelmann et al 2007).
In terms of durability of results, ﬁ  llers can be classiﬁ  ed 
as follows: Short lasting – up to 6 months; long lasting or 
semi permanent – up to 3 years; and permanent – more than 
3 years.
Independently of the product, the ideal characteristics of 
soft-tissue ﬁ  lling material have been identiﬁ  ed. They include 
acceptable ﬁ  ller longevity, biocompatibility, non-migratory, 
low adverse event proﬁ  le, and a reasonable cost-beneﬁ  t ratio 
(Jansen and Graivier 2003; Rohrich et al 2003; Marmur et al 
2004; Tzikas 2004; Felderman 2005; Broder and Cohen 2006; 
Burroughs and Anderson 2006; Dover 2006; Jacovella 2006; 
Sengelmann et al 2007).
With reference to the above-mentioned classiﬁ  cations, 
calcium hydroxylapatite (CaHA) may be considered a 
synthetic and long-lasting/semipermanent dermal ﬁ  ller. 
Radiesse® offers many of the desirable mentioned properties 
of a facial ﬁ  ller, particularly for deep dermal defects (Elson 
2006) and for non-surgical contouring augmentation (Busso 
and Karlsberg 2006).
Product description
Radiesse® (Bioform Medical Inc. USA) is a sterile, latex-free, 
non-pyrogenic, semi-solid, cohesive subdermal, injectable 
implant, whose principal component is synthetic CaHA, a 
biocompatible material with over 20 years of use in medicine 
(Hobar et al 2000; Havlik et al 2002). The product is sup-
plied in 1.3 mL disposable syringes with Luer-lock ﬁ  ttings. 
(Bioform Medical Inc 2007). The semi-solid nature of the 
product is created by suspending CaHA microspheres of 
25–45 micron diameter in a gel carrier that consists primarily 
of sterile water and glycerin. The gel structure is formed by 
the addition of a small amount of carboxymethylcellulose 
(USP). The gel is dissipated in vivo and replaced with soft 
tissue growth, while the CaHA remains at the site of injection 
(Bioform Medical Inc. 2007).
CaHA is biodegradable, following the same metabolic 
pathway as bone debris resulting from common bone frac-
tures. After 2–3 months, the carboxymethylcellulose is 
resorbed and replaced by collagen. Finally a gradual break-
down of the particles occurs, until complete phagocytosis 
is achieved (Misiek and Kent 1984; Probeck and Rothstein Clinical Interventions in Aging 2008:3(1) 163
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1989; Pettis et al 1990; Flaharty 2000; Sklar and White 
2004). The CaHA microspheres present in Radiesse have 
the same chemical composition as the inorganic constituent 
of teeth and bone, and exhibit an extensive safety proﬁ  le 
(Havlik et al 2002). As a bioceramic, CaHA is native to the 
body with no antigencity. Moreover, the biocompatibility 
of CaHA has been extensively tested in preclinical studies, 
and it has been shown to be non-toxic and non-mutagenic 
(Flaharty 2000).
Clinical, histologic, and electron microscopic ﬁ  ndings 
after in vivo injections have demonstrated excellent toler-
ance. Biocompatibility studies on CaHA implants have 
all been characterized by minimal, if any, inﬂ  ammatory 
response, with no foreign body reaction and without evidence 
of local or systemic toxicity (Flaharty 2000; Havlik et al 
2002; Marmur et al 2004).
When injected as small microspheres, CaHA acts as a 
scaffold that promotes new tissue formation similar to its 
surrounding environment. Inside soft tissues such as the 
dermis, deposited particles support ﬁ  broblastic ingrowth 
and new collagen formation, without calciﬁ  cation. In other 
words, the properties of CaHA mimic the environment into 
which it is placed. No osseous inﬁ  ltration has been found. 
No migration from the sites of injection has been observed 
(Felderman 2005).
After opening the syringe, the unused material after ﬁ  rst 
treatment can be recapped and kept for the same patient until 
3 months, for future administration. It is important that no 
visible air bubbles are present inside the syringe to avoid 
future hardening of the material.
Regulatory status
With many injectable dermal ﬁ  llers on the market, the Ameri-
can Society of Plastic Surgeons and the American Society 
for Aesthetic Plastic Surgery clariﬁ  ed legal and regulatory 
issues (American Society of Plastic Surgeons and American 
Society of Aesthetic Plastic Surgery 2006).
Radiesse is considered a “medical device”. It has already 
received FDA approval for esthetic facial augmentation in 
the US. Such approval includes the long-lasting correction 
of moderate to severe facial wrinkles and folds, and the 
treatment of facial fat loss due to immunodeﬁ  ciency virus 
infection.
The product also has approval for plastic and reconstruc-
tive surgery, including soft tissue augmentation for the facial 
area in the following countries: Argentina, Canada, Israel, 
Mexico, Romania, Turkey, and all countries within the EU 
(Bioform Medical Inc. 2007). Radiesse is not appoved in 
Australia for cosmetic indications. It is advisable to determine 
the regulatory status of the country in which the clinician is 
practicing.
Radiesse is provided with 3 self-adhesive identiﬁ  cation 
labels with the following data: lot number, quality control 
number, and last date allowed to be used.
Indications
Esthetic facial main indications 
and contraindications
What results are to be expected – subtle or quite spectacular? 
It depends on the patient’s look before treatment with ﬁ  llers 
and on their speciﬁ  c expectations. Indications have to be 
carefully discussed in advance with the physician, remember-
ing that some signs of aging will be attenuated but will not 
disappear. According to speciﬁ  c facial conditions, treatments 
have to be selected in order to better treat the cases.
Sagging skin almost always suggests a surgical solution. 
Intracutaneous rhytides due to sun exposure are better treated 
with laser resurfacing or chemical peels. Patients with deep 
furrows, vertical glabellar lines, and nasolabial folds are very 
good candidates for facial ﬁ  llers such as Radiesse (Roy et al 
2006). Several facial regions can be injected in order to ame-
liorate or enhance some features: glabellar lines, subdermal 
support of the brows, malar and buccal fat pads, tear troughs, 
nasolabial folds, nose, lips, perioral region, marionette lines, 
oral commisures, and chin, among others.
Radiesse is also a good solution to correct some lesions 
such as acne scars. In a preliminary study of 10 patients, 
Goldberg and colleagues (2006) noted that saucerized acne 
scars responded well to treatment but ice-pick scars did not.
Other aging signs such as crow’s feet are partly a con-
sequence of dynamic expression of the orbicularis oculi 
muscles. Due to the possibility of “speed bump-like nodules”, 
Radiesse is not an ideal product for this region. Moreover, 
patients with one or more of the following conditions should 
not receive Radiesse implants: acute or chronic skin infection 
that involves the site to be treated, existing keloidal scars, 
systemic collagen diseases, severe bleeding disorders, and 
presence of foreign bodies such as silicone (Jacovella 2006). 
Individuals with body dysmorphic disorders and unrealistic 
expectations should no be injected with Radiesse either.
Other medical indications
Evans and co-workers presented an interesting article on the 
use of CaHA for nipple projection after failed nipple-areolar 
reconstruction (Evans et al 2005). Although the study described 
early results with only 6 patients, the technique appears to be Clinical Interventions in Aging 2008:3(1) 164
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promising. This initial pilot study suggests that Radiesse is 
an effective, safe, and reliable method for immediate results, 
according to subjective data and patient satisfaction.
In addition to esthetic use, Radiesse has been successfully 
used in the following conditions: stress urinary incontinence, 
vesicoureteral reﬂ  ux, vocal cord augmentation, and as a 




The procedures can be performed in an ofﬁ  ce setting on an 
outpatient basis. Patients must provide speciﬁ  c informed 
consent for the treatment with Radiesse for soft tissue aug-
mentation before initiation of the procedures (Reisman 2006). 
It is advisable to keep identiﬁ  cation stickers with the product 
data attached to the medical record.
The areas to be injected must be appropriately marked 
with the patient in an upright position. As with all esthetic 
surgical and dermatological procedures, pretreatment pic-
tures are mandatory.
Patients must be warned to avoid agents that can cause 
bleeding, for example, aspirin and some anti-inﬂ  ammatory 
drugs, for 7 days prior to injection, which can help reduce 
hematoma formation (Narins and Bowman 2005).
Patient position
Treatments are usually performed with the patient in a sitting 
or semi-sitting position, which allows the physician to inject 
the desired sites while effects of gravity inﬂ  uence the skin.
Anesthesia
Depending on the anatomical area, patient’s sensitivity, and 
personal medical preferences, regional inﬁ  ltrative or nerve 
block anesthesia may be used. In a very interesting and 
instructive article on local and regional block anesthesia, 
Gmyrek and Dahdah (2006) present many interesting guide-
lines about this important subject. The following techniques 
can be applied before Radiesse injections.
Topical anesthesia
The suggested drug is betacaine 10% as a gel applied to the 
treatment area for at least 15–20 minutes before Radiesse 
injection.
Inﬁ  ltrative anesthesia
Inﬁ  ltrative anesthesia has the advantage of a rapid onset of 
action after injection. Because inﬁ  ltration of the substance 
frequently distorts the landmarks of the site, the area to be 
anesthetized must be identiﬁ  ed and marked preceding the 
injection.
Nerve blocks
Nerve blocks are helpful mainly when the inﬁ  ltration of the 
anesthetic solution may cause undesirable distortion of the 
surgical site or require an amount of anesthetic that exceeds 
the maximum recommended dose. Because most nerves are 
subdermal, it is recommended that the local anesthetic is 
placed in a subcutaneous location using a 30-gauge needle. 
According to the regions to be treated, the most common 
nerve territories can be blocked as follows.
Supraorbital and supratrochlear block: The supraorbital 
and supratrochlear nerves innervate the frontal part of scalp 
and forehead. Both nerves are branches of the ﬁ  rst division 
or ophthalmic branch of the trigeminal nerve (Gmyrek and 
Dahdah 2006).
Supraorbital and supratrochlear nerve blocks can be 
approached from either the area of the supraorbital foramen 
or the area of the supratrochlear notch. For this region, 1 mL 
per side is adequate.
Infraorbital block: The infraorbital nerve innervates the 
lower eyelid, medial aspect of the cheek, upper lip, and lateral 
portion of the nose. It is a branch of the second division or 
maxillary branch of the trigeminal nerve. The infraorbital 
nerve leaves the skull through the infraorbital foramen, which 
is 1 cm inferior to the infraorbital ridge.
There are two approaches for infraorbital block: through 
direct trans-cutaneous injection or via intra-oral injection. In 
both cases, the infraorbital foramen should be palpated and 
the drug injected near but not into the canal that surrounds 
the nerve, in order to avoid nerve injury. An average dose 
of 2 mL is suggested.
Mental nerve block: The mental nerve innervates the 
lower lip and chin. It is a branch of the third division or 
mandibular portion of the trigeminal nerve. The mental nerve 
exits the skull through the mental foramen. The intraoral 
approach is preferred. The needle has to be inserted in the 
inferior labial sulcus at the apex of the ﬁ  rst bicuspid. An aver-
age dose of 1.5 mL is sufﬁ  cient to block the inferior lip.
Combination techniques
Some techniques can be combined for minimizing discomfort 
during anesthetic injection. They include the use of topical 
anesthetic on the skin or into the mucosa and the use of ice 
cubes, before performing inﬁ  ltrative or nerve block anes-
thesia. Generally topical anesthetic may be used prior to Clinical Interventions in Aging 2008:3(1) 165
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applying the ice (Comite et al 2007). Since topical anesthesia 
itself is not often enough to avoid pain, combination tech-
niques are strongly recommended.
Injection techniques: general guidelines
Some considerations must be taken into account to select 
a technique: area to be treated, depth of the injection, and 
desired injecting volume.
Needle selection is the next step. As a general rule, the 
smallest needle-gauge should be used that can deliver the 
product appropriately (Murray et al 2005). The suggested 
needles are 27-gauge 0.25 and 25-gauge 0.25 inch (6 mm) 
long. The product must be injected in the deep dermis or sub-
dermally, placing the needle with an angle of 30–45 degrees 
(Jacovella 2006; Jansen and Graivier 2006).
Intradermal or superﬁ  cial dermal injections are not rec-
ommended because they can cause visible white nodules in 
the superﬁ  cial dermis (Flaharty 2000; Fagien 2006). After 
the needle is introduced in the proper plane, the product is 
injected in the created tract during slow withdrawal of the 
syringe. Needle adaptations may include bending to access 
particular contours of the face.
As a practical rule it is advisable to gradually achieve 
the ﬁ  nal results over several sessions (Narins and Bowman 
2005).
Different speciﬁ  c maneuvers can be used depending on 
the above-mentioned factors: linear threading, serial punc-
ture, fanning, and cross hatching.
In linear threading the needle is introduced along the 
entire fold or wrinkle, longitudinally in a subcutaneous plane. 
Depending on the anatomical structures to be ﬁ  lled, one, two, 
or three bands of the product are delivered in parallel rows, 
as the needle is withdrawn. In the serial puncture technique 
small amount amounts of the product are injected one beside 
the other, perpendicularly to the fold. The fanning technique 
involves a radial trajectory of the needle from the puncture 
site with a delicate back and forth movement. The product 
is delivered as the needle is withdrawn. In the cross hatching 
technique the product is injected from two different perpen-
dicular approaches. Linear and parallel threading deposits 
can be made from different sites in one direction and some 
deposits can be are made perpendicularly to the ﬁ  rst.
Speciﬁ  c techniques according 
to different regions
Glabellar vertical lines
The glabellar wrinkles and furrows develop during progres-
sion of aging progression due both to static and dynamic 
factors. Such lines usually pose little problem for implants 
because of the thickness of the dermis (Figure 1).
Although some concerns about tissue necrosis and seri-
ous complications such as embolization have been noted in 
the literature, no adverse effects have been observed by the 
author (Jacovella 2006; Jacovella et al 2006). Nevertheless, 
caution should be the rule and treatment of this area by the 
trainee injector is not advised.
To anesthetize the region, a supratrochlear block with 
0.5 mL of lidocaine per side is sufﬁ  cient.
To correct the vertical lines, a 27-gauge, 0.5-inch 
(12-mm)-long needle is used in a linear threading deposi-
tion. The needle is introduced longitudinally into the deep 
dermis to create a tunnel; CaHA is then injected into the 
created space by simultaneously slowly withdrawing the 
syringe and pressing the compound from the syringe into 
the dermis.
To reduce muscle movement, better results are obtained 
by previous treatment with botulinum toxin. This procedure 
allows for weakening of the brow depressors (Flaharty 2000; 
Kanchwalla et al 2005; Jacovella 2006).
The suggested amount of Radiesse is 0.3–0.5 mL.
Cheek and infraorbital region
Small or not very noticeable cheeks and lack of infraorbital 
projection as individual or ethnic features are frequent indi-
cations for ﬁ  llers in patients looking for a simple youthful 
look (Figure 2). Some patients are aware of a sunken upper 
maxillary facial region as a sign of illness or tiredness. 
Radiesse can provide volume augmentation to ameliorate 
this aspect. By restoring structural support and fullness of 
the malar and submalar areas, the shadowing effect associ-
ated with aging of the region can be diminished, resulting 
in a better appearance.
It is advisable to plan augmentation of cheek and adja-
cent areas in the context of the whole face, not only just the 
overlying malar eminence (Busso and Karslberg 2006). The 
treatment should be planned in consultation with the patient 
(Jansen and Graivier 2006). Inﬁ  ltrative or nerve block anes-
thesia can be used in such areas.
A 25-gauge, 1-inch (25-mm)-long needle is recom-
mended. The puncture site must be distal to the desired area 
to be injected and the combination of cross-hatching and 
fanning techniques is preferred to allow adequate spread of 
the product. Depth of injection is of paramount importance 
in this area. Jansen and Graivier (2006) propose beginning 
injecting in the more superior aspect of the zone, in the direct 
subermal subcutaneous plane. Better results are achieved Clinical Interventions in Aging 2008:3(1) 166
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Figure 1 Pre-treatment (A) and post-treatment (B) at 9 months after 0.5 mL of Radiesse, in a 65-year-old woman with two static vertical glabellar lines.
when multiple ﬁ  ne threads are delivered in multiple planes, 
allowing the scaffolding effects of tissue in-growing among 
the product (Busso and Karlsberg 2006).
After product placement, immediate molding is advis-
able to smooth the surface and achieve the desired shape. 
Overcorrection is hardly ever necessary. However, some 
clinicians prefer to overcorrect in anticipation of initial 
partial resorption. The suggested volumes for this area are 
2–4 mL, even though 1 mL per side can provide a subtle 
noticeable result.
Nose
Even though conventional esthetic rhinoplasty remains 
the treatment of preference for the most important nasal 
deformities, injectable facial ﬁ  llers may provide an attractive 
alternative in minor defects (Figures 3 and 4). Moreover some 
internal nasal valve collapse after previous surgery or trauma 
can be ﬁ  nd repaired by injecting HA ﬁ  ller.
Mastery of both nasal anatomy and precise surgical 
technique is mandatory before performing nasal corrections 
with ﬁ  llers (Fagien 2006).
The following anatomical regions can be implanted in 
order to improve esthetic appearance: fronto-nasal angle, 
dorsum, nasal tip, and naso-labial angle.
Patients can be injected once, twice, or thrice, starting 
always with a low volume. As is the case with other areas of 
treatment with Radiesse, but especially in this one, overcor-
rection is to be avoided.
A
Figure 2 Pre-treatment (A) and post-treatment (B) at 18-month follow up of a 44-year-old woman with sunken upper maxillary anatomical region. The implant of 1.5 mL of 
Radiesse provided an enhanced infra-orbital area. The patient was injected by Dr. Miles Graivier.
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The suggested maximum volumes for each of the nasal 
regions are: fronto-nasal angle, 1.5 mL; dorsum, 0.5 mL; tip, 
0.5 mL; and nasolabial angle, 1.5 mL.
Besides esthetic indications, Radiesse can provide 
improvement in some cases of nasal ﬂ  ow impairment.
In a very interesting paper, Nyte (2006) describes spreader 
graft injection with Radiesse for a non-surgical solution in 
internal nasal valve collapse in 23 patients.
Some causes such as prior rhinoplasty, nasal trauma, 
or weakness of the upper lateral cartilages can result in an 
internal valve collapse.
Before proceeding with the implantation, a Q-tip can be 
used to displace the involved upper lateral cartilages and 
therefore simulate the spreader graft effect.
With the aid of a head lamp and a nasal speculum, small 
drops (0.05 mL) of CaHA are injected into the submucoperi-
chondrial and submucosal planes at the junction points of the 
upper lateral cartilages and the dorsal cartilaginous septum. 
Patients with and without previous surgery are suitable 
for CaHA implants. In order to avoid distortions, supra-
trochlear and infraorbital nerve block anesthesia is rec-
ommended. A waiting time of 10–15 minutes diminishes 
bleeding.
Proceeding with back and forth multidirectional technique, 
and by using delicate and limited fanning soft movements with 
a 27- or 25-gauge needle connected to the syringe, the physi-
cian can create a subcutaneous space to hold the ﬁ  ller. The 
product is injected in the previously created space during slow 
withdrawal of the needle. Placing the puncture site distal to 
the regions to be corrected is strongly recommended.
Because of the many sebaceous glands in the nasal tip, 
approaching this area from the dorsum with a 25-gauge, 
1-inch (25-mm)-long needle is desirable.
Micropore-like tapes can be applied around the corrected 
areas in order to provide desired shape and diminish swell-
ing deformities.
Figure 3 Pre-treatment (left) and post-treatment (right) at a 12-month follow up, in a proﬁ  le view of a 42-year-old woman with a primary aesthetic rhinoplasty. Enhancement 
of tip projection was achieved with 0.5 mL. No touch-up was necessary after ﬁ  rst implant.Clinical Interventions in Aging 2008:3(1) 168
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A 23-gauge, 1.5-inch (37-mm) needle and 0.10–0.15 mL are 
proposed (Nyte 2006). The area must be carefully inspected 
after each injection.
The CaHA provides support to this area and allows 
air ﬂ  ow improvement, due to the corresponding increase 
of the internal nasal valve angle. Some middle external 
vault fullness due to temporary edema can be expected as 
adverse effect.
Although this indication appears to be safe, convenient, 
and cost-effective alternative to conventional graft surgery, 
closed or open rhinoplasty, with and without autologous 
cartilages, are still the ﬁ  rst preference in most of nasal defor-
mities, both esthetic and functional.
Mid face lipoatrophy associated with HIV
First described in 1998, lipodystrophy syndrome is character-
ized by peripheral lipoatrophy, central lipohypertrophy and 
other signs and symptoms (Silvers et al 2006). Lipoatrophy 
refers to the loss of subcutaneous fat in the face, arms, legs, 
and buttocks. Although the pathogenesis of this syndrome 
is not fully understood, recent hypotheses suggest that 
impairment of adipocyte differentiation may play a role in 
this disease.
Facial lipoatrophy likely results in part from infection 
with HIV and in part from highly active antiretroviral treat-
ment as a consequence of the infection. Fat loss is most 
notably in the cheeks and can cause severe psychological 
effects because it can be an identifying stigma of HIV infec-
tion (Comite et al 2006; Silvers et al 2006).
Inﬁ  ltrative anesthesia is suggested. The product must be 
injected in the deep subcutaneous plane by a cross-hatching 
technique. Depending of the degree of hollowness caused 
by the absence of fat tissue, volumes may vary from patient 
to patient. Silvers et al (2006) proposed amounts from 
2 to 20 mL, considering several injections in the same areas.
Considering the lack of fat in these patients, Radiesse 
appears to be a very good option as volume ﬁ  ller.
Nasolabial folds
The nasolabial folds are one of the most frequently treated facial 
areas (Figures 5 and 6). The physician should begin by determin-
ing the amount of skin redundancy with a pinch test. Depending 
on the surgeon’s experience, if the redundancy is too large, a 
surgical face lift could be considered (Jacovella 2006).
Some degree of natural asymmetry is common and part 
of an individual’s beauty. For this reason, time to observe 
Figure 4 Pre-treatment (left) and post-treatment (right) at a 12-month follow up, in ¾ view of the same patient as in Figure 3.Clinical Interventions in Aging 2008:3(1) 169
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and identify subtle asymmetries must be taken in account, 
and discussed with the patient according to their expectations 
(Jansen and Graivier 2006).
After marking the area to be treated, 1 mL of inﬁ  ltrative 
anesthesia per side is injected and a 10-minute waiting time 
is recommended. Some authors such Alam and Yoo (2007) 
suggest miniblocks of 0.2 mL of 0.5% lidocaine, injected into 
the sulcus superior to the third incisor bilaterally.
The product may be injected the ﬁ  rst time to achieve a 
moderate correction and proceed with a touch-up, 4 weeks 
later. In the folds, a 25-gauge, 1-inch (25-mm)-long needle 
or a 27-gauge, 1.25-inch (31-mm) needle can be chosen. 
The smaller one is sufﬁ  cient to deliver the material smoothly 
without clogging. Nonetheless the 25-gauge allows a thicker 
layer in one delivery.
Two techniques or the combination of both can be per-
formed: linear and serial puncture (Jacovella 2006; Alam 
and Yoo 2007).
To perform the ﬁ  rst, the needle is introduced along the 
entire fold longitudinally in a subcutaneous plane, starting at 
the inferior end and advancing up to the nose. Depending on 
the depth of the folds, one, two, or three bands of Radiesse 
must be implanted in parallel rows, through the same starting 
puncture. There is no need to remove the needle between 
A B
Figure 5 Pre-treatment (A) and post-treatment (B) of a 52-year-old woman with noticeable nasolabial folds. After 0.5 mL in each side and a touch-up at 3 months, the results 
are shown after a 12-month follow up period. The total amount in each side was 0.8 mL.
B A
Figure 6 Pre-treatment (A) and post-treatment (B) of the same patient as in Figure 5, in ¾ view.Clinical Interventions in Aging 2008:3(1) 170
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threads. As the needle is withdrawn, the product is injected 
while the passive hand of the operator palpates the area and 
feels the deliver of the material.
The serial puncture technique, perpendicular to the fold, 
is suggested as a structural support. In this case, the product 
should be delivered in a deeper plane ﬁ  rst and completed 
with the linear mentioned maneuver.
Suggested volumes are 0.5–1.5 mL per side.
The ﬁ  ller material can be massaged and modeled to ensure 
even placement and to avoid an irregular surface appearance. 
With the operator’s index ﬁ  nger inside the mouth and the 
thumb outside, the whole length of the nasolabial fold is 
compressed to create a ﬂ  at shaped material deposit (Alam 
and Yoo 2007).
Lips
The lips are considered one of the key features of facial beauty. 
The ideal lip augmentation procedure should grant predictable 
results without visible scars. The high number of techniques 
available for lip enhancement reﬂ  ects the lack of an ideal and 
completely reliable method with predictable and reproducible 
results. Some of them include complex surgical techniques 
and the use of autologous or synthetic materials.
Dermal ﬂ  aps and superﬁ  cial musculoaponeurotic ﬂ  aps, 
for example, may present serious complications such as 
asymmetry, noticeable scars, and bridge restriction scars. 
These scars, if not hypertrophic, can be quite apparent 
and may necessitate permanent application of camouﬂ  age 
cosmetics. Despite corrections remaining for 5 years, such 
procedures imply prolonged surgical techniques (Jacovella 
2006).
Other materials such as polytetraﬂ  uoroethylene semi-
solid implants offer permanent augmentation results. Seg-
ments of the product have to be cut to shape and size and 
introduced through an incision in the posterior labial mucosa. 
Despite achieving permanent results, the need for temporary 
sutures, a mandatory 2 days of liquid diet, and the possibil-
ity of malposition, are considered disadvantages compared 
with ﬁ  llers.
Many indications are taken into account in the aging 
mouth: vertical wrinkles, reduction in vermillion height, 
disappearance of Cupid’s bow, and low volume of the lips.
According to these signs it is very important to help the 
patient deﬁ  ne the speciﬁ  c goals of treatment.
The biggest disadvantage of permanent ﬁ  llers is their per-
manence. If the desired results are not achieved, removal of 
these permanent ﬁ  llers is difﬁ  cult at best and even sometimes 
impossible (Jacovella et al 2006).
Because of the greater degree of motion, lip augmentation 
with ﬁ  llers is not as forgiving as in the nasolabial region. 
For that reason previous training and delicate technique are 
mandatory (Kanchwala et al 2005).
Radiesse can provide long-lasting results without the 
above-mentioned drawbacks of both surgical and non-
surgical techniques.
Troncular anesthesia is strongly recommended. Infra-
orbital nerve and mental nerve blocks provide effective 
anesthesia and reduce the chance of unacceptable 
distortion sometimes seen in direct inﬁ  ltration (Gymrek 
and Dahdah 2006).
A 27-gauge or 25-gauge, 1-inch (25-mm)-long needle can 
be selected for this area, to limit the number of punctures and 
to diminish both the incidence of bleeding and hematomas. 
The preferred plane is between the mucosal border and the 
orbicular oris muscle. The speciﬁ  c technique consists of cre-
ating two puncture wounds for each side, since each half of 
the length of the upper lip and lower lip has to be approached 
from the two corners of the mouth (Jacovella et al 2006).
To avoid involuntary spreading, special care should be 
to hold the lip ﬁ  rmly with the thumb and the foreﬁ  nger of 
the passive hand, while introducing the needle with the other 
hand. Only one-layer injections of 0.5 mL per site are sug-
gested, while softly withdrawing the needle.
When lip fullness is desired in addition to vermillion 
enhancement, a deeper second line can be injected. The phil-
tral columns have to be treated separately with a 27-gauge 
0.25-inch (6-mm) needle (Jacovella 2006).
The total ideal amount is no more than 1 mL for each 
lip, at least during the ﬁ  rst treatment. Beginning with low 
volumes is always advisable, especially in the treatment of 
lips (Figures 7 and 8).
To avoid speed bump-like deformities, vertical lines 
should not be directly ﬁ  lled. The linear threading technique 
itself can help remove ﬁ  ne radial rhytids, as the overlying 
skin stretches out. Nevertheless, some practitioners prefer to 
ﬁ  ll such lines directly (Jansen and Graivier 2003, 2006).
Other areas
Chin and jawlines can be treated very similarly to cheeks. 
Because the patient’s physiognomy can signiﬁ  cantly change 
from supine to upright positions, the patient must be posi-
tioned in the Frankfurt plane to determine some important 
areas such as central dimple creation and prejowl sulcus 
defects (Jansen and Graivier 2006).
The subcutaneous plane allows easy molding and shaping 
around the inferior border of the mandible. Special care must Clinical Interventions in Aging 2008:3(1) 171
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be taken to avoid product displacement and the appearance 
of “witch chin” deformity.
Facial asymmetries can be also corrected depending on 
the required volume.
Treatment combinations
Radiesse can be combined with some other ﬁ  llers, such as 
hyaluronic acid, and with botulinum toxin, laser resurfacing, 
different dermal peels, and radiofrequency treatments.
Godin and colleagues presented an interesting study 
in which Radiesse and non-animal hyaluronic acid are 
combined to improve facial enhancement (Godin et al 
2006). Many patients have received semipermanent ﬁ  ll-
ers after temporary ﬁ  llers without interference (Lemperle 
et al 2006).
Botulinum toxin can decrease dynamic wrinkles prior to 
Radiesse implant. In this way, especially in glabellar furrows 
and marionette lines, ﬁ  lling effects can be improved. It is 
recommended to start with botulinum toxin and wait for at 
least a week before proceeding with CaHA.
Combination treatments such as laser, chemical peels, 
and dermabrasion should be performed before facial ﬁ  ller 
injection. Because long-lasting implants usually lie in a 
dermal deep plane, they are not affected by laser (Lemperle 
et al 2006).
In an experimental preclinical study, Shumaker et al 
(2006), presented the effects of monopolar radiofrequency 
over soft tissue ﬁ  llers. The preliminary results showed an 
increase in ﬁ  broplasia and collagen deposition surrounding 
Radiesse.
Every patient’s circumstances and treatment needs 
are different. Each case must be considered as unique 






Figure 7 Pre-treatment (A), immediate at 24 hours post-treatment (B), after 15 days (C), and at 12 months post-treatment (D) of a 68-year-old woman. The total amounts 
were 0.7 mL for the upper lip and 0.5 mL for the lower lip. No touch-ups were performed after ﬁ  rst injection.Clinical Interventions in Aging 2008:3(1) 172
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A B
Figure 8 Pre-treatment (A) and post-treatment (B) of the previous patient in a ¾ view. Despite a previous lip asymmetry, a total amount of 1.2 mL of Radiesse in both lips
provided enhancement and projection of vermilion border and ﬁ  ltrum. Radial lip lines were lessened.
Results
Since beauty is in the eye of the beholder, discussing results 
is difﬁ  cult. No ﬁ  ller can stop time. Longevity, patients’ 
satisfaction, adverse events, and complications all inﬂ  uence 
how results are interpreted.
Longevity
How long will the effects last? How long depends on many 
factors and cannot exactly be predicted. Longevity depends 
on many factors, such as the patient’s age and metabolism, 
and the relative dynamic motion of the area in which the 
implant is placed (Felderman 2005).
Real “persistence of the product” in the body versus “clinical 
visible effect” concepts must be clearly explained, discussed, 
and understood by the patient before every treatment.
Many published reports state that results achieved dur-
ing the ﬁ  rst post-procedural month or after the last touch-up 
when needed remain almost unchanged until 12 months. 
After 12–18 months, the achieved volumes begin to dimin-
ish, though some results can be noted 24 months post injec-
tion. The average longevity therefore could be considered 
to be 12–18 months (Tzikas 2004; Kanchwala et al 2005; 
Broder and Cohen 2006; Jacovella 2006; Jacovella et al 
2006; Jansen and Graivier 2006; Silvers et al 2006). Longer 
duration of effect, up to 24 months, can be seen in some 
patients, with a touch-up at the 12th month of half the amount 
injected the ﬁ  rst time (Felderman 2005; Jacovella 2006).
Patient satisfaction
Patient satisfaction results for Radiesse have been assessed in 
several studies. In a possible self-reporting options range very 
good, good, acceptable, and non-acceptable, Jacovella et al 
reported 87% of very good results in a preliminary study (Jacov-
ella et al 2006). Tzikas (2004) presented a patient satisfaction 
response of 47% excellent and 41% good. Jansen and Graivier 
(2006) concluded that 89% of 609 patients would choose 
Radiesse again. Roy and colleagues presented an overwhelming 
positive response to the look and feel of the implant, averaging 
4.6 on a grading scale from 1 to 5 (Roy et al 2006).
Unpleasant effects 
and complications
Most of the unpleasant effects and complications associated 
with Radiesse injection are technique-related (Jacovella 
2006).
Unpleasant effects
As temporary adverse effects, ecchymosis and hematoma 
may be expected in approximately 5% of patients. Redness 
and swelling immediately after treatment is very frequent. 




Nodules and granulomas have been described as complica-
tions. Lip nodules are relatively frequent because of product 
crowding, and are technique-associated. Granulomas are 
due to excessive immunological reaction and are not that 
frequent.
According to Kanchwala et al (2005), Radiesse should 
not be injected in lips because of a high incidence of mucosal Clinical Interventions in Aging 2008:3(1) 173
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nodules, but another study has shown a low incidence of lip 
nodules (Jacovella et al 2006).
Both nodules and granulomas can be treated with triam-
cinolone local injection at ﬁ  rst time or through a small inci-
sion in persistent cases (Zide 2003; Jacovella 2006; Jansen 
and Graivier 2006).
Asymmetries
Asymmetries can occur immediately after injections. It is 
wise to refrain from additional treatment for at least 2 or 3 
weeks, until the acute inﬂ  ammatory effects disappear. After 
that time, persistent asymmetries can be corrected, starting 
always with small amounts of the product.
Comments and conclusions
The high number of available injectable facial ﬁ  llers is 
increasing steadily. The election of the most appropriate 
ﬁ  lling material is based on multiple factors, including, most 
importantly, patient safety ﬁ  rst, longevity, cost-effectiveness, 
precise indications, and regulatory status, among others. 
Consequently it is advisable to make the best decision, con-
sidering the right products, at the right place, at the right time 
(Werschler 2006). Any procedure performed on an elective 
basis must have a predictable result.
Several other types of facial ﬁ  ller compounds can be 
mentioned. Autologous fat transfer by injection has been 
proposed for large volume bulking purposes. Despite the 
advantage of being the own patient’s tissue, two other dis-
advantages can be considered. First, it implies two surgical 
procedures: taking the fat and injecting the fat. Second, last-
ing results are unpredictable, even though permanence can 
be improved by adding endothelial growth factor.
Taking into account that aging is a continuous process, 
persistence of permanent ﬁ  llers can be disproportional to the 
loss of connective tissue, and visible bumps in some regions 
could result in an unesthetic appearance.
Because of many complications such as big granulomas, 
migration of product, serious deformities, and systemic reac-
tions, silicone injections should not be used. The signiﬁ  cant 
drawback of injectable liquid silicone is that the product and 
the respective reactive tissue cannot be removed without 
consequent deformity.
Short-lasting ﬁ  llers such as hyaluronic acid could be 
used to demonstrate expected results when these are not 
well understood by the patient, and also for training pur-
poses. Frequent touch-ups, every 6 months, should be taken 
into account when making a decision on such temporary 
products.
Finally, Radiesse can be considered an effective 
soft-tissue ﬁ  ller in view of its overall advantages. Much 
published research shows that calcium hydroxylapatite is safe 
and well tolerated when used properly. Most of the desirable 
properties of a dermal ﬁ  ller can be achieved with Radiesse, 
including acceptable longevity, biocompatibility, low rate of 
side effects, and a reasonable cost-beneﬁ  t ratio.
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